Stratos Wealth Partners’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History

Stratos Wealth Partners’s Portfolio PTLA Stock Details PTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-21	Closed	-$1K	–	2846
2018 Q3	$1K	Buy	+21	New	+$686	﹤0.01%	2921
2018 Q2	–	Sell	-196	Closed	-$6K	–	2931
2018 Q1	$6K	Buy	196 +175	+833%	+$7.68K	﹤0.01%	2571
2017 Q4	$1K	Buy	+21	New	+$1.06K	﹤0.01%	2770

Other funds holding PTLA

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

CCM

Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JSP

Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Stratos Wealth Partners's PTLA Position: Q4 2018 in Review

Stratos Wealth Partners sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q4 2018, closing a stake of 21 shares — an estimated $1K sold.

Stratos Wealth Partners first reported a position in PTLA in Q4 2017 and held it in 3 quarters. The position peaked at $6K in Q1 2018. 181 funds tracked by Wall St. Rank hold PTLA as of Q4 2018.

Stratos Wealth Partners reported no remaining Portola Pharmaceuticals, Inc. position as of Q4 2018 after selling out during the quarter.
Stratos Wealth Partners sold 21 Portola Pharmaceuticals, Inc. shares in Q4 2018, an estimated $1K.
Stratos Wealth Partners first reported a position in Portola Pharmaceuticals, Inc. in Q4 2017 and held it in 3 quarters.
Stratos Wealth Partners's Portola Pharmaceuticals, Inc. position peaked at $6K in Q1 2018.
181 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q4 2018.

Based on Stratos Wealth Partners's 13F filing for Q4 2018, filed 8 Feb 2019.